Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Publication Date Aug 2013
Publisher MP ADVISORS
Product Type Report
Single User License help $ 2500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favorable outcomes recently.  New targets have been validated in this process where kinases lead the way.  Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for the Relapsed and Refractory Multiple Myeloma (RRMM) and their successful commercial launch validate the strategy deployed by the companies.  We expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML).  Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium.  The successful IPOs’ of Ambit and Onconova are indicators of the optimism prevailing amongst the investors, Patients and Physicians community.
The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts.  The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.  Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report.

Key Points Discussed in the Report –
Overview of the disease and Unmet need
Drugs in the pipeline – Mechanism of Action (MoA) and Clinical Stage of development
Myelodysplastic Syndromes –  Lower-risk, Higher-risk, and recurrent / refractory MDS
Acute Myeloid Leukemia – Untreated/ newly diagnosed and relapsed / refractory AML
Key milestones
Launch Timeline and Commercial Opportunity of Late-stage pipeline (RR MDS and RR AML)
M&A and Licensing deals in the last 5 years
In-licensing and/or M&A Opportunity
Detailed Company analysis includes Clinical data of drugs , Milestones, and Valuation
Ambit Biosciences (AMBI)
Onconova Therapeutics (ONTX)

Table of Contents
1. Executive Summary
2. Investment Drivers of The Select Companies Covered
3. Myelodysplastic syndrome (MDS)
3.1 Disease Overview
3.2 Unmet Need
3.3 Current Standard of Care
3.3.1 Supportive Care
3.3.2 Low-Intensity Therapy
3.3.3 High-Intensity Therapy
3.3.4 Recurrent/ Refractory or relapsed MDS
4. Acute Myelogenous Leukemia (AML)
4.1 Disease Overview
4.2 Current Standard of Care
4.2.1 AML pts younger than 60 years
a Induction Therapy
b Post-remission/ consolidation therapy
4.2.2 AML pts Older than 60 years
a Current treatment options – Hypomethylating agents and SCT
4.3 Unmet Need
4.4 Refractory or relapsed AML
5. Competitive Landscape: RR/ High-Risk MDS and RR AML
6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML
7. Key Milestones
8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML)
9. Drivers of M&A / Licensing Deals in MDS/ AML
9.1 Select M&A Deals in Last 5 Years – 2007 to 2012
9.2 Select Licensing Deals in Last 5 Years – 2007 to 2012
9.3 M&A and Licensing Deals Opportunity
10. Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)
10.1 Ambit Biosciences (AMBI)
10.1.1 Investment Drivers
10.1.2 Other Assets – Not Fully valued in the Price
10.1.3 Key Milestones
10.1.4 NPV Valuation – Scenario Analysis (Early Approval)
10.1.5 Background about AMBI’s products
a. Quizaritinib – Key profile, Clinical Data, IP protection
b. Other assets – CEP-32496, AC410, & AC708
c. Competitive Landscape – Late- and Mid-stage AML drugs
d. Select JAK 2/1 Inhibitor: Late- and Mid-stage Pipeline
10.2 Onconova Therapeutics (ONTX)
10.2.1 Investment Drivers
10.2.2 Upside from Early-stage pipeline
10.2.3 Strong IP position
10.2.4 Key Milestones
10.2.5 NPV Valuation
10.2.6 Background about ONTX’s products
a. Estybon (rigosertib) – Key Profile, Primary Indications
b. Rigosertib IV – 2nd-line Higher-Risk MDS (clinical data and competition landscape)
c. Rigosertib Oral – 1st-line Lower-Risk MDS (clinical data and competition landscape)
d. Estybon (rigosertib) – Label Expansions
Metastatic Pancreatic cancer
Head and Neck cancer
e. Other Early-stage drugs – ON 013105, Recilisib
f. Preclinical Programs – ON 1231320, ON 123300, ON 108600, ON 044580
g. Patents
h. Collaboration/ Partnership Agreements

Title Date Price
2012 Deep Research Report on China Human Albumin Industry
By QYResearch
2012 Deep Research Report on China Human Albumin Industry was professional and depth research report on China Human Albumin industry. This report has firstly introduced Human Albumin definition classi ...Read More
Nov 2012 $2000.00
2013 Deep Research Report on Global and China Human Coagulation Factor Ⅷ Industry
By QYResearch
2013 Deep Research Report on Global and China Human Coagulation Factor Ⅷ Industry is a professional and depth research report on Global and China Human Coagulation Factor Ⅷ industry. This ...Read More
Mar 2013 $2200.00
2014 Deep Research Report on Global and China Glutamate Dehydrogenase Industry
By QYResearch
<2014 Deep Research Report on Global and China Glutamate Dehydrogenase Industry> was professional and depth research report on Global and China Glutamate Dehydrogenase industry. The report first ...Read More
May 2014 $2200.00
2014 Deep Research Report on Global And China Nucleotide Industry
By QYResearch
<2014 Deep Research Report on Global And China Nucleotide Industry> was professional and depth research report on Global and China Nucleotide Industry. The report firstly introduced Nucleotide b ...Read More
Jan 2014 $2200.00
2014 Deep Research Report on Global And China Pectinase Industry
By QYResearch
<2014 Deep Research Report on Global And China Pectinase Industry> was professional and depth research report on Global and China Pectinase industry. The report firstly introduced Pectinase basi ...Read More
Mar 2014 $2200.00
2014 Deep Research Report on Global and China Xylose Industry
By QYResearch
<2014 Deep Research Report on Global and China Xylose Industry> was professional and depth research report on Global and China Xylose industry. The report firstly introduced Xylose basic informa ...Read More
Jun 2014 $2200.00
Argentina Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Argentina Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new report, ...Read More
Nov 2012 $2500.00
Asia-Pacific Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Asia-Pacific Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new repor ...Read More
Nov 2012 $3500.00
Australia Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Australia Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new report, ...Read More
Nov 2012 $2500.00
Austria Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Dental Biomaterials, Crowns and Bridges and Others
By GlobalData
Austria Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Dental Biomaterials, Crowns and Bridges and OthersSummaryGlobalData’s new report ...Read More
Nov 2012 $2500.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z